Emergence of oral GLP-1 obesity treatments and market dynamics

Eli Lilly and Novo Nordisk, two leading players in the global obesity treatment market, have initiated a new head-to-head competition in the market for oral GLP-1 receptor agonists. Novo Nordisk received approval for its oral semaglutide-based Wegovy pill in December 2025, while Eli Lilly launched its orforglipron-based Foundayo in April 2026. This signals a rapid shift in the obesity treatment market from high-cost injectables to convenient and affordable oral pills, which are expected to attract patients who prioritize ease of administration and those who are averse to injections.

Commercial strategy of significantly reduced pricing for oral pills

Injectable GLP-1 treatments can cost between $900 and $1,400 per month without insurance, posing a major barrier to long-term patient adherence. In fact, approximately 74% of patients who discontinue prescriptions cite cost as the primary reason, making drug pricing a critical factor for commercial success. In response, both companies drastically reduced the starting price of their oral treatments—Wegovy pill and Foundayo—to around $149 per month for out-of-pocket payments, effectively removing patient entry barriers. This aggressive pricing strategy serves as a defense mechanism to bring patients back from compounding pharmacies or illicit counterfeit drug markets into the formal treatment market.

Eli Lilly's strengths revealed in prescribing preference surveys

According to a prescribing preference survey conducted by Spherix Global Insights among 185 healthcare providers, Eli Lilly's product line recorded high satisfaction rates. Satisfaction with the injectable Zepbound reached 80%, significantly outperforming Novo Nordisk's injectable Wegovy at 59%. The oral treatments, Foundayo and Wegovy pill, are in a tight race. Healthcare providers particularly praised Eli Lilly's tirzepatide-based products for faster and more sustained weight loss and better tolerability. In contrast, Novo Nordisk's Wegovy pill was noted to require strict fasting and hydration restrictions, which could place Eli Lilly in a prescribing advantage in the future competitive landscape.

Contrasting revenue trends and the future value of the obesity treatment market

Recent financial results showed Eli Lilly's revenue exceeded $23 billion in the second quarter, driven by the explosive growth of Zepbound and Mounjaro, representing a 48% year-over-year increase. According to Evaluate reports, the annual revenue of Lilly's tirzepatide-based treatments is projected to reach $70 billion by 2032, demonstrating its strong market dominance in the near term. In comparison, Novo Nordisk's Wegovy pill recorded $354 million in the first quarter, followed by a slight slowdown in the second quarter. Meanwhile, Lilly's Foundayo also underperformed slightly in its initial second-quarter revenue of $98 million. Future global market share expansion for both companies will ultimately depend on supply chain stabilization and the extent of insurance coverage expansion.